Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
See us soon
Craig CM, McLaughlin TL
doi: 10.2337/dc20-0498 70 LinXLiH
Key Clinical Findings from Rose Pharma Studies: Proven Appetite Suppression: Completed proof of concept study, demonstrated that ROSE-010 significantly reduces food consumption and slows gastric emptying Rapid Onset, Short Duration: Begins working within 20 minutes and clears within a few hours, minimizing side effects Reduced GI Side Effects: Unlike long-acting GLP-1s, ROSE-010s shorter half-life lowers the period of nausea and GI distress Improved Tolerability: Targets appetite without prolonged drug exposure, making it an ideal maintenance therapy Why the Market Needs ROSE-010 60-85% of GLP-1 patients need an effective weight loss maintenance strategy Current solutions focus on weight lossPeople need long-term weight loss management options ROSE-010 offers a flexible, meal-time approach to prevent weight regain Real-world data shows that long-term GLP-1 adherence is low yet patients need tools to sustain their progress
US$ 22.17
US$ 24.52
US$ 25.87
US$ 25.06
US$ 25.51
